Drug intelligence / Profile preview

PF-08046876

Development stage: Phase 1
Lead developer: Pfizer
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

PF-08046876 is an investigational antibody-drug conjugate (ADC) composed of an anti-integrin beta-6 (IB6) antibody conjugated to a camptothecin-class topoisomerase I (TOP1) inhibitor payload. It is designed to selectively bind IB6, a cell-surface protein overexpressed in certain solid tumors, enabling targeted cytotoxic delivery to tumor cells while sparing non-target tissues. PF-08046876 is in early clinical development by Pfizer for the treatment of various advanced solid tumors, including non-small cell lung cancer, pancreatic cancer, gastric cancer, head and neck cancer, and others[1][3][4][5][7][9].

Targets

TOP1 (DNA Topoisomerase I)αVβ6 (Integrin αVβ6)

Beyond the preview

Go deeper on PF-08046876.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-08046876.

Explore the full profile